Activities per year
Activities
- 11 results
Search results
-
Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do
Bart Neyns (Speaker)
13 Sep 2024 → 17 Sep 2024Activity: Talk or presentation › Talk or presentation at a conference
-
Checkpoint blockade and CNS tumour microenvironment
Bart Neyns (Invited speaker)
6 Dec 2023 → 8 Dec 2023Activity: Talk or presentation › Talk or presentation at a conference
-
Checkpoint blockade and CNS tumour microenvironment
Bart Neyns (Invited speaker)
6 Dec 2023 → 8 Dec 2023Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent glioblastoma.
Wietse Geens (Speaker), Stephanie Du Four (Contributor), S VAN LAERE (Contributor), Julia Katharina Schwarze (Contributor), Gil Awada (Contributor), Michaël Bruneau (Contributor), Jens Tijtgat (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor) & Bart Neyns (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial
Bart Neyns (Presenter)
8 Dec 2021 → 11 Dec 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial
Julia Katharina Schwarze (Speaker), Wietse Geens (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), Anne-Marie Van Binst (Contributor), Hendrik Everaert (Contributor), Laura Seynaeve (Contributor), Alex Michotte (Contributor), Michaël Bruneau (Contributor), I VAN RIET (Contributor), Sandra Tuyaerts (Contributor), Johnny Duerinck (Contributor) & Bart Neyns (Contributor)
16 Sep 2021 → 21 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Gil Awada (Speaker), Ibrahim Özdemir (Contributor), Julia Katharina Schwarze (Contributor), Emma Daeninck (Contributor), Odrade Gondry (Contributor), Yanina Jansen (Contributor), Teofila Seremet (Contributor), Marleen Keyaerts (Contributor), Hendrik Everaert (Contributor) & Bart Neyns (Contributor)
14 Dec 2018Activity: Talk or presentation › Talk or presentation at a conference
-
Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program
Jeroen De Filette (Speaker), Yanina Jansen (Contributor), Max Schreuer (Contributor), Bert Bravenboer (Contributor), Bart Neyns (Contributor) & Brigitte Velkeniers-Hoebanckx (Contributor)
30 Jan 2016Activity: Talk or presentation › Talk or presentation at a conference